Oxaprost

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxaprost

Quick Facts

Property Description
Active Ingredients Diclofenac, Misoprostol
Form Tablet (Oral Route)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID) and Prostaglandin E1 Analog combination
Primary Function Anti-inflammatory and Gastroprotective
Origin Synthetic

What Type of Medicine is the Diclofenac-Misoprostol Combination?

Oxaprost is a fixed-dose combination product designed for oral route administration as a tablet. It contains two distinct synthetic active ingredients: the Nonsteroidal Anti-inflammatory Drug (NSAID), Diclofenac, and the Prostaglandin E1 Analog, Misoprostol. This combination, which may also be known by the synonymous brand name Arthrotec, is classified primarily as a gastroprotective drug combination, distinguishing it from single-agent anti-inflammatory treatments. The specialized structure addresses the need for effective inflammation reduction while mitigating the risk of gastrointestinal complications, a feature recognized for supporting patient tolerance when long-term NSAID therapy is required.


Composition: What are the Active Ingredients in Oxaprost?

The core of this medicine is composed of the active ingredients Diclofenac and Misoprostol. Diclofenac serves as the primary component for reducing swelling and discomfort and is chemically recognized as a phenylacetic acid derivative. Misoprostol is included specifically to protect the stomach and intestinal lining, functioning as a synthetic analog of Prostaglandin E1, a protective substance naturally found in the body. The combination ensures that the potent anti-inflammatory action is paired directly with a defensive strategy against gastric damage.


What is the General Benefit of Combining Diclofenac and Misoprostol?

The general benefit of this combination is to provide effective pain relief and inflammation reduction while simultaneously offering active protection for the stomach lining. The Diclofenac component works to alleviate symptoms by lowering the substances that cause inflammation. Concurrently, the Misoprostol component reinforces the stomach's natural defense by increasing protective mucus and decreasing stomach acid secretion. The addition of Misoprostol reduces the incidence of NSAID-induced ulcers. This dual functionality offers a comprehensive therapeutic approach where symptom relief is achieved alongside proactive support for gastrointestinal health.

What side effects are possible with Oxaprost?

Possible Side Effects and Safety Information

The safety profile of the Diclofenac-Misoprostol combination is defined by the officially documented adverse reactions related to its NSAID and prostaglandin analog components. Adverse reactions are formally classified by frequency and system-organ class in regulatory documents, with the most frequently reported effects impacting the gastrointestinal system.

Documented Adverse Reactions and Frequencies

Classification Examples of Reactions
Very Common Diarrhea, Abdominal pain
Common Nausea, Dyspepsia, Flatulence, Headache, Dizziness, Vomiting, Skin Rash
Rare Gastrointestinal perforation, Ulceration, Hepatitis, Anaphylactic reaction

These frequencies establish that gastrointestinal disturbances like diarrhea and abdominal pain are the most expected effects, frequently appearing early in the course of therapy. Other common effects include those involving the nervous system (headache, dizziness) and skin.

Serious Adverse Reactions and Population Constraints

The official labeling includes specific safety constraints for critical, potentially life-threatening risks. The Misoprostol component results in an absolute contraindication in pregnancy due to the risk of uterine hemorrhage and fetal toxicity. The Diclofenac (NSAID) component is associated with warnings regarding serious, potentially fatal cardiovascular thrombotic events (such as stroke and myocardial infarction) and gastrointestinal bleeding, ulceration, and perforation. This medicine is also subject to specific safety notes regarding increased risk in older adults for serious gastrointestinal events and is contraindicated in patients with established cardiovascular disease or advanced renal impairment. The risk of these serious events may also increase with the duration of use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of the Diclofenac-Misoprostol combination may present with documented manifestations from both active components. Reported signs include gastrointestinal effects such as nausea, vomiting, stomach pain, diarrhea, and potentially GI bleeding. Central Nervous System (CNS) signs may involve dizziness, drowsiness, confusion, tremor, and seizures. Severe systemic effects can include hypotension, bradycardia, and acute renal or hepatic damage.

Overdose is associated with the potential for life-threatening outcomes, including GI perforation, cardiovascular thrombotic events (myocardial infarction, stroke), and severe hypersensitivity reactions. The Misoprostol component introduces a critical, unique risk: the product is contraindicated in pregnancy, and overdose carries the risk of uterine rupture, abortion, premature birth, or birth defects.

Regulatory guidance mandates that individuals seek immediate medical attention or call emergency services right away if an overdose is suspected or if severe symptoms like collapse, seizure, trouble breathing, or signs of a stroke occur. No specific antidote is known for this combination. Treatment is symptomatic and supportive, and official procedures may include the use of oral activated charcoal if administered soon after ingestion.

Therapeutic Uses of Oxaprost

Oxaprost is a combination medicine used in the management of the signs and symptoms associated with certain chronic inflammatory conditions. Its purpose is to address the discomforts of joint pain, stiffness, and swelling that occur with these conditions.

This medication is primarily used for patients managing conditions such as osteoarthritis and rheumatoid arthritis. It is designated for use in adult patients who require ongoing Nonsteroidal Anti-inflammatory Drug (NSAID) therapy but are also considered to be at a heightened risk for developing NSAID-induced gastric or duodenal ulcers and related complications. The therapeutic goal is to support mobility and comfort during the necessary course of anti-inflammatory treatment.

Quick Fact: Relief for Joint Pain and Inflammation

Eligibility and Restrictions for Use

Who Can and Cannot Use Oxaprost?

This section defines the official eligibility criteria for Oxaprost (diclofenac sodium and misoprostol combination product) as stipulated in government regulatory documents.


Absolute Contraindications

Use of this medicine is strictly forbidden for the following populations:

  • Pregnant Women: Due to the risk of uterine rupture, abortion, premature birth, and birth defects associated with the misoprostol component.
  • Patients with known hypersensitivity to diclofenac, misoprostol, aspirin, or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
  • Patients undergoing treatment for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Patients with active gastrointestinal bleeding or perforation.

Conditional and Restricted Use

Eligibility for certain groups requires special consideration and monitoring:

  • Women of Childbearing Potential (WOCBP): Use is conditional. These patients must have a negative pregnancy test and commit to using effective contraceptive measures during therapy.
  • Geriatric Patients: Are at increased risk for serious gastrointestinal and cardiovascular events. Use is generally not recommended in those with cardiovascular or renal risk factors.
  • Patients with Severe Heart Failure or Advanced Renal Disease: Use is generally avoided unless the anticipated benefits clearly outweigh the risks.

Age-Group Eligibility

  • Pediatric Patients: Use and safety in the pediatric population are not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies several drug-drug and drug-substance interaction patterns for Oxaprost, driven by the actions of both the Diclofenac (NSAID) and Misoprostol components.

Classification Interacting Agents / Substances Documented Interaction Outcome
Contraindicated Pregnancy; Other Non-Aspirin NSAIDs; CABG Surgery Prohibited due to abortifacient risk or additive gastrointestinal/cardiovascular toxicity.
Pharmacodynamic Warfarin, Aspirin, SSRIs/SNRIs Increased risk of serious gastrointestinal and non-gastrointestinal bleeding.
Pharmacodynamic ACE Inhibitors, ARBs, Diuretics May diminish the antihypertensive or natriuretic effect of these medicines.
Pharmacokinetic Lithium, Methotrexate Increases the plasma concentrations and reduces the renal clearance of these agents.
Food/Substance Magnesium Antacids; Food; Alcohol/Tobacco Antacids reduce misoprostol availability; Food decreases misoprostol maximum concentration; Alcohol/Tobacco increase bleeding risk.

The drug's interaction structure mandates strict restrictions, including the prohibition of co-administration with other NSAIDs to avoid cumulative gastrointestinal risk. The pharmacokinetic interactions primarily involve Diclofenac inhibiting the elimination of certain drugs, leading to elevated exposure. Furthermore, the official label highlights that the exposure of the misoprostol component is approximately doubled in patients with severely impaired renal function.

Mechanism of Action

How Oxaprost Works


Enzyme Inhibition: Attenuation of Inflammatory Signaling

This core mechanistic domain is governed by Diclofenac's action as an inhibitor of Cyclooxygenase-2 ( COX-2) enzyme activity. By blocking this enzyme, the drug suppresses the creation of prostaglandin E2 ( PGE2), a key mediator in the modulation of nociceptive receptor sensitivity and localized edema. This molecular blockade helps limit the impact of excessive mediator activity, leading to a systemic decrease in inflammatory mediator levels and the attenuation of peripheral nerve sensitization.


Receptor Agonism: Enhancement of Gastric Epithelial Barrier Function

The mechanism's second component, Misoprostol, is a synthetic PGE1 analog that functions as an agonist on specific Prostaglandin E (EP) receptors in the stomach lining. Activating these receptors initiates a cellular cascade that stimulates the secretion of protective mucus and bicarbonate while also increasing mucosal blood flow. This results in a strengthening of the gastrointestinal epithelial barrier, supporting the modulation of protective pathway activity.


Functional Compensation of Opposing Mechanisms

The combination represents a strategy of functional compensation, where Misoprostol's receptor agonism counteracts the localized COX-1 inhibition caused by Diclofenac in the stomach. This design is relevant in systems where targeted pathway adjustment is required: the drug engages mechanisms that regulate overactive inflammatory processes while simultaneously initiating pathways that support epithelial barrier integrity, which is compromised by the primary systemic action.

Dosage and Administration Information

How to Use Oxaprost (Misoprostol / Diclofenac-Misoprostol)

Instructions for using medicines containing Misoprostol (often branded as Oxaprost or as a component in Diclofenac/Misoprostol combination products) outline the required administration rules and procedural constraints. These instructions apply to various labeled uses, which dictate the specific route and frequency.

Administration Routes and Dosing

The medicine is administered via Oral, Vaginal, or Buccal routes, depending on the specific regimen. The dose and frequency follow the prescription.

Purpose (Regimen Dependant) Administration Route General Frequency Administration Rule
NSAID-Related Prophylaxis Oral Two to four times daily ( b.i.d. to q.i.d.) Take Diclofenac/Misoprostol with food; swallow tablets whole.
Labor Induction Oral or Vaginal Pulsed (e.g., every two hours) Administer in a hospital setting with continuous monitoring.

Procedural and Patient Constraints

Tablets intended for oral use, such as the Diclofenac combination, must be swallowed whole and not chewed or crushed. The combined tablet should be taken with food. For specific uses, such as the induction of labor, the medicine must only be administered in a hospital setting under the supervision of trained personnel, ensuring immediate access to continuous monitoring and emergency care.

Women of childbearing potential taking the Diclofenac/Misoprostol combination are required to use effective contraception throughout the course of therapy. For patients with renal or hepatic impairment, a lower dose or longer dosing interval may be necessary when the medicine is used for labor induction.

Recent Clinical Evidence

Research evidence / Overview of studies for Oxaprost

Evidence for Symptom Management in Arthritis

The diclofenac-misoprostol combination was studied for its use in organized clinical research, primarily through short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time for adults with osteoarthritis (OA) or rheumatoid arthritis (RA), conditions marked by functional limitations and periods of heightened symptoms. The research examined outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort.

Studies conducted during periods of increased symptom activity reported that the findings describe patterns observed in the observed populations, which were consistent with patterns observed in studies of other anti-inflammatory agents. Research highlights changes measured during the study period, focusing on temporary physiological imbalance linked to inflammatory states.

Evidence for Gastrointestinal Ulcer Prevention

One of the primary research focuses for this combination was evaluated in research exploring its use concerning gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs (NSAIDs). The evidence base includes specialized endoscopic studies. These studies focused on patients who were taking NSAIDs for arthritis and who were considered to be at high risk for complications.

Research explored the incidence rates of endoscopically defined gastric and duodenal ulcers and reported that the rates were lower in the group receiving the misoprostol component compared to the NSAID-only group. This evidence contributes to the broader evidence landscape by providing insight into short-term changes in gastrointestinal integrity when the two components are used together.

Long-Term Studies and Extended Follow-up

Most major efficacy and ulcer prevention studies for the diclofenac-misoprostol combination have focused on intermediate-term follow-up, commonly lasting 12 weeks. However, long-term effects are not fully established, and there is limited information for outcomes that are assessed over many months or years. Long-term outcomes, such as the sustained durability of reported response or the assessment of serious clinical events, are often inferred from the shorter-term ulcer incidence data, and direct, extended-duration research is still emerging.

What Research Gaps Remain

Several research limitation frames are noted in the scientific literature. While the evidence level for short-term ulcer prevention is generally high, comparative evidence is lacking for certain alternative treatment strategies. Specifically, there is limited information from direct head-to-head trials comparing the diclofenac-misoprostol combination against an alternative gastroprotective approach, such as taking an NSAID alongside a proton pump inhibitor (PPI).

Frequently Asked Questions (FAQ)

Common questions about Oxaprost (FAQ)


Q: Is Oxaprost the same as other arthritis medications or pain relievers?

No. Official documents classify Oxaprost as a fixed-dose combination product containing two distinct active ingredients. The structure addresses the need for anti-inflammatory action while mitigating the risk of gastrointestinal complications, a feature distinguishing it from single-agent NSAID treatments.


Q: Does the diarrhea side effect from Oxaprost usually go away on its own?

Diarrhea is one of the most common expected side effects of the medicine, often occurring early in the course of therapy. Regulatory information indicates that this gastrointestinal effect is frequently self-limiting, meaning it may resolve without intervention. Diarrhea has been reported as resolving within approximately eight days in some studies.


Q: Are there any long-term side effects associated with taking Oxaprost?

Official labeling notes that the risk of serious side effects associated with the NSAID component, particularly those affecting the heart and stomach, may increase with the duration of use. Therefore, consistent medical follow-up is relevant when this medicine is used over an extended period.


Q: Can Oxaprost be taken with other pain medications or over-the-counter NSAIDs?

Co-administration with other non-aspirin NSAIDs is generally avoided or not recommended in regulatory labeling due to the potential for an additive risk of serious gastrointestinal events. Official product information also states that the use of analgesic (pain-relieving) doses of aspirin is not generally recommended with this medicine.


Q: Can Oxaprost affect the results of any common medical lab tests?

The medicine is associated with risks to the blood, which regulatory documents refer to as Hematologic Toxicity. For this reason, official safety information advises monitoring for changes in red blood cell count, such as hemoglobin or hematocrit levels, in certain at-risk patients.


Q: Is Oxaprost safe for people with a history of heart problems or high blood pressure?

The official label advises that use should be avoided in patients who have pre-existing severe heart failure. Furthermore, the NSAID component can cause new or worsened high blood pressure, and official information advises monitoring blood pressure.


Q: How quickly can someone expect to feel the effects of Oxaprost for arthritis pain?

The gastroprotective component begins its documented activity approximately 30 minutes after oral administration. The onset of the anti-inflammatory effect is described separately in product information and is not the same as the initial misoprostol activity.


Q: How long does the effect of a single Oxaprost tablet typically last?

Official dosing regimens for this medicine are prescribed to be taken two to four times daily. This dosing schedule is used to maintain consistent therapeutic levels of the drug components in the body.


Q: How does Oxaprost affect the cardiovascular system?

The drug is associated with an increased risk of serious cardiovascular thrombotic events, which include heart attack (myocardial infarction) and stroke. The medicine can also cause fluid retention or edema and lead to new or worsening high blood pressure.


Q: What if I'm currently breastfeeding and considering Oxaprost?

Regulatory labels note that components of the medicine are present in breast milk, and specific guidance from a healthcare provider is recommended before use during breastfeeding.


Q: Does Oxaprost have a risk of causing allergic skin reactions?

Official documents list skin rash as a common adverse event reported in clinical trials. Additionally, there are specific safety warnings regarding the potential for rare but serious skin reactions, such as Stevens-Johnson Syndrome (SJS), which would require immediate discontinuation.


Q: Does Oxaprost interact with antacids that contain magnesium?

Yes, official safety information recommends that co-administration with magnesium-containing antacids should be avoided. This is because they can potentially worsen the diarrhea associated with the misoprostol component of Oxaprost.


Q: Is a headache a common side effect of Oxaprost?

Yes, regulatory documents list headache as an adverse event reported in clinical trials. It is described as a common effect, with some studies reporting its incidence at more than 1% of patients.


Q: Does Oxaprost cause weight gain or fluid retention?

Official labeling notes that fluid retention and edema (swelling due to fluid buildup) have been observed in some patients taking the NSAID component and related drugs. This is an effect noted for monitoring.


Q: Can Oxaprost affect one's sleep patterns?

Official product information lists both Insomnia (difficulty sleeping) and Drowsiness as reported adverse events for the diclofenac/misoprostol combination. These effects involve the central nervous system.


Q: What signs might indicate a potentially serious reaction to Oxaprost?

Official documents advise that signs such as chest pain, shortness of breath, weakness, slurring of speech, or signs of bleeding (like black stool) should be immediately reported to a healthcare provider.


Q: Does Oxaprost carry any specific warnings for individuals who smoke?

Yes. Official regulatory labeling for the NSAID component highlights that the risk of serious gastrointestinal events, such as ulceration, bleeding, and perforation, is increased in patients who smoke.


Q: Is there a generic version of Oxaprost available?

Yes. The drug is available as a generic name product, which is known as Diclofenac Sodium and Misoprostol Delayed-Release Tablets. This is in addition to the original brand name product.


Q: Why do some people refer to the ingredients in Oxaprost separately?

People may refer to the ingredients separately because the product contains two distinct active components, Diclofenac and Misoprostol. Each ingredient has its own unique function and separate history of clinical use before being combined into this single pill.


Q: Can Oxaprost be used for pain that is not related to arthritis?

The official indications for the diclofenac/misoprostol combination product are explicitly for the relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. Regulatory approval is based on the evidence for use in these specific inflammatory conditions.


Q: Is it normal to experience increased gas or bloating when first starting Oxaprost?

Yes. Flatulence (gas) and abdominal pain are commonly reported gastrointestinal adverse events. Regulatory documents list these effects in the very common and common categories of side effects.


Q: What is the difference between Oxaprost 50 and Oxaprost 75?

The different numbers, such as 50 and 75, typically refer to the strength of the diclofenac component in the tablet. The different strengths available for the product represent differing doses of the diclofenac component, while the misoprostol component is generally a fixed dose.


Q: Does Oxaprost require routine blood monitoring?

Official labeling advises that monitoring of blood pressure, hemoglobin or hematocrit levels, and liver function tests may be relevant for certain patients during therapy.


Q: How does Oxaprost affect people with Inflammatory Bowel Disease (IBD)?

The misoprostol component may cause severe diarrhea. Therefore, regulatory documents advise that patients with an underlying gastrointestinal condition such as Inflammatory Bowel Disease (IBD) should be monitored carefully.


Q: What makes Oxaprost's ulcer-preventing ingredient work differently from a proton pump inhibitor?

The misoprostol component is classified as a Prostaglandin E1 Analog. It works by physically strengthening the stomach’s natural protective lining and stimulating mucus, which is a different mechanism than Proton Pump Inhibitors, which primarily work by reducing the amount of stomach acid produced.


Q: Can a male patient who takes Oxaprost pose any risk to a pregnant partner?

The regulatory warnings for this medicine focus exclusively on the direct exposure of a pregnant woman to the drug itself. No specific regulatory warnings are provided regarding risk to a pregnant partner from the semen of a male patient taking the medicine.


Q: Can Oxaprost cause dizziness or drowsiness?

Yes, official product information lists both dizziness and drowsiness as adverse events affecting the central nervous system that have been reported with the use of this medicine.


Q: What should a patient do if they develop unusual bruising or bleeding while on Oxaprost?

The drug is associated with increased bleeding risk, and any unusual bleeding or bruising should be discussed with a healthcare provider.


How should Oxaprost be stored and disposed of?

How to Store and Dispose of Oxaprost?

Strict adherence to official storage and disposal instructions ensures the product remains effective and safe. Oxaprost must be stored at controlled room temperature, generally defined as at or below 25 C (77 F). The medication must be kept in its original container, tightly closed, and protected from excess heat and moisture. Storage in the bathroom is prohibited.

Child-Safety and Accessibility

Keep this medicine strictly out of the sight and reach of children.

Disposal

The preferred method for disposing of unused or expired medication is through a local drug take-back program. If a program is not available, the medication should be mixed with an unappealing substance, such as dirt or used coffee grounds, and then sealed inside a plastic bag before being placed in the household trash. Do not crush the tablets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxaprost found in:

A-Z Index: